News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Nassir Habboubi

Articles by Nassir Habboubi

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

ByJavier Cortés, MD,François-Clément Bidard,Aditya Bardia, MD, MPH,Virginia G. Kaklamani, MD, DSc,Ioanna Vlachaki,Giulia Tonini,Nassir Habboubi,Philippe Aftimos

August 17th 2024

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

ByAditya Bardia, MD, MPH,Francois Clement Bidard,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Philippe Aftimos,Javier Cortes,Simona Scartoni,Nassir Habboubi,Virginia Kaklamani, MD, DSc

April 28th 2023

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

ByErika P. Hamilton, MD,Sung-Bae Kim,Neelima Vidula, MD,Simona Scartoni,Tarek Sahmoud, MD,Bartomeu Piza Vallespir,Kathy Puyana Theall,Nassir Habboubi,Nuhad Ibrahim, MD

April 27th 2023

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

What Path to Approval Has Dasatinib Taken in CML/ALL?

How Can Lower-Income Countries Maintain Representation in Clinical Trials?

© 2025 MJH Life Sciences^®

All rights reserved.